特发性非肝硬化性门静脉高压症的研究进展

摘要/Abstract

摘要： 特发性非肝硬化性门静脉高压症(INCPH)是一种罕见的血管性肝病,近年来引起了人们新的关注。INCPH在组织学改变、血流动力学特征和临床结果方面与肝硬化不同。重要的是,其病因和发病机制尚不清楚,但已确定与肝内血管疾病的发展有关,并在排除引起门静脉高压的其他原因(如肝硬化以及其他导致门静脉高压的窦前性、窦性、窦后性原因和内脏静脉血栓形成)后做出的。此外,特发性非肝硬化性门静脉高压症的总体预后优于肝硬化患者,但对症治疗(控制胃食管静脉曲张出血和预防血栓形成)仍是主要治疗方法。目前临床上对INCPH的认识相对不足,对该病易发生误诊,本文通过目前对INCPH研究进展的阐述,以提高临床医生对此病的认识。

关键词: 特发性非肝硬化性门静脉高压症, 肝内血管疾病, 窦前性, 食管胃静脉曲张

陶然, 张晓春, 胡锦, 曹杨港, 毛德文. 特发性非肝硬化性门静脉高压症的研究进展[J]. 肝脏, 2023, 28(3): 366-369.

参考文献

[1] Kmeid M, Liu X, Ballentine S,et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data. Gastroenterology Res, 2021,14:49-65.
[2] Riggio O, Gioia S, Pentassuglio I, et al. Idiopathic noncirrhotic portal hypertension: current perspectives. Hepat Med, 2016,27:81-88.
[3] Schouten JN, Garcia-Pagan JC, Valla DC, et al. Idiopathic non cirrhotic portal hypertension. Hepatology, 2011,54:1071-1081.
[4] Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: An appraisal. J Pathol Transl Med, 2016,50:17-25.
[5] Schouten JN, Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare Dis, 2015,30:67.
[6] Koot BG, Alders M, Verheij J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension. J Hepatol, 2016,64:974-977.
[7] Vilarinho S, Sari S, Yilmaz G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology, 2016,63:1977-1986.
[8] De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019,4:399-411.
[9] Vispo E, Cevik M, Rockstroh JK, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis, 2013,56:1117-1122.
[10] Verheij J, Schouten JN, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology, 2013,62:1083-1091.
[11] Pulvirenti F, Pentassuglio I, Milito C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. J Immunol Res, 2014,1-8.
[12] Agrawal M, Rahmani R, Nakkala K, et al. Hepatoportal sclerosis (obliterative portal venopathy) and nodular regenerative hyperplasia in a patient with myasthenia gravis: A case report and review of the published work. Hepatol Res, 2013,43:999-1003.
[13] Kotani K, Kawabe J, Morikawa H, et al. Comprehensive screening of gene function and networks by DNA microarray analysis in Japanese patients with idiopathic portal hypertension. Mediators Inflamm, 2015,1-10.
[14] Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology, 2019,156:1582-1599.
[15] Gioia S, Nardelli S, Ridola L, et al. Causes and Management of non-cirrhotic portal hypertension.Curr Gastroenterol Rep, 2020,22:56.
[16] Sato Y, Nakanuma Y. Role of endothelial-mesenchymal transition in idiopathic portal hypertension. Histol Histopathol, 2013,28:145-154.
[17] Bissonnette J, Rautou PE, Valla DC. Idiopathic non-cirrhotic portal hypertension: An update. Presse Med, 2015,44:1009-1015.
[18] Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology, 2014,59:2276–2285.
[19] Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther, 2012,35:1424-1433.
[20] Riggio Oliviero. Idiopathic noncirrhotic portal hypertension: current perspectives.Hepat Med, 2016,27:81-88.
[21] Khanna R, Sarin SK. Non-cirrhotic portal hypertension. J Hepatol,2014,60:421-441.
[22] Muhammad ZK, Muhammad UK, Safi UK, et al. Atrial fibrillation is a risk factor for worse outcomes in patients with end stage liver disease. J Atr Fibrillation, 2020,12:2248.
[23] Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int, 2018,12:148-167.
[24] Goel A, Ramakrishna B, Muliyil J, et al. Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis.Dig Dis Sci,2013,58:179-187.
[25] Seijo S, Lozano JJ, Alonso C, et al. Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension.Am J Gastroenterol, 2013,108:926-932.
[26] Rajesh S. Non-cirrhotic portal hypertension: an imaging review. Abdominal radiology (New York),2018,43:1991-2010.
[27] Zhao ZL, Wei Y, Wang TL, et al. Imaging and pathological features of idiopathic portal hypertension and differential diagnosis from liver cirrhosis. Sci Rep,2020,10:2473.
[28] Elkrief L, Lazareth M, Chevret S, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology, 2021,74:364-378.
[29] Bissonnette J, Garcia-Pagan JC, Albillos A, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology, 2016,64:224-231.
[30] De Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI consensus workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63:743-752.
[31] European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver. J Hepatol, 2016,64:179-202.
[32] Gioia S, Nardelli S, Pasquale C, et al. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. Dig Liver Dis, 2018,50:839-844.